Rhabdomyolysis and fluctuating asymptomatic hyperCKemia associated with CACNA1S variant

European Journal of Neurology

Volumn 25, Issue 2, 2018, Pages 417-419

  Anandan, C ^a   Cipriani, M A ^a   Laughlin, R S ^a   Niu, Z ^a   Milone, M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cav1.1; CACNA1S; cores; hyperCKemia; rhabdomyolysis

Indexed keywords

ARGININE; CALCIUM; CAV1.1 CALCIUM CHANNEL; CREATINE KINASE; LEUCINE; OXIDOREDUCTASE; RYANODINE RECEPTOR 1; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; CACNA1S PROTEIN, HUMAN; CALCIUM CHANNEL;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CACNA1S GENE; CALCIUM TRANSPORT; CASE REPORT; CLINICAL ARTICLE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYPE CREATINE KINASE EMIA; HYPERMETABOLISM; HYPOKALEMIC PERIODIC PARALYSIS; MALE; MUSCLE BIOPSY; MUSCLE CELL; PHENOTYPE; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RECEPTOR GENE; RHABDOMYOLYSIS; RYR1 GENE; SANGER SEQUENCING; SARCOPLASMIC RETICULUM; ANIMAL; BLOOD; GENETICS; PATHOPHYSIOLOGY;

ADULT; ANIMALS; CALCIUM CHANNELS; CREATINE KINASE; HUMANS; MALE; RHABDOMYOLYSIS;

EID: 85039154223     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13528     Document Type: Article

References (14)

1. Wu J, Yan Z, Li Z, et al. Structure of the voltage-gated calcium channel Ca(v)1.1 at 3.6 A resolution. Nature 2016; 537: 191–196.
2. Ptacek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994; 77: 863–868.
3. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316–1325.
4. Fan C, Lehmann-Horn F, Weber MA, et al. Transient compartment-like syndrome and normokalaemic periodic paralysis due to a Ca(v)1.1 mutation. Brain 2013; 136: 3775–3786.
5. Schartner V, Romero NB, Donkervoort S, et al. Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy. Acta Neuropathol 2017; 133: 517–533.
6. Schiemann AH, Stowell KM. Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia. Br J Anaesth 2016; 117: 124–128.
7. Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol 2015; 5: 761–790.
8. Yang B, Yang Y, Tu W, Shen Y, Dong Q. A rare case of unilateral adrenal hyperplasia accompanied by hypokalaemic periodic paralysis caused by a novel dominant mutation in CACNA1S: features and prognosis after adrenalectomy. BMC Urol 2014; 14: 96.
9. Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNLIA3): genotype/phenotype correlation for two predominant mutations and evidence for the absence of a founder effect in 16 Caucasian families. Am J Hum Genet 1995; 56: 374–380.
10. Eltit JM, Bannister RA, Moua O, et al. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2++ channel and the type 1 ryanodine receptor. Proc Natl Acad Sci USA 2012; 109: 7923–7928.
11. 1S-subunit. Am J Physiol Cell Physiol 2010; 299: C1345–1354.
12. Weiss RG, O'Connell KMS, Flucher BE, et al. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III−IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004; 287: C1094–C1102.
13. Roux-Buisson N, Monnier N, Sagui E, et al. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test. Br J Anaesth 2016; 116: 566–568.
14. Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F. 217th ENMC International Workshop: RYR1-related Myopathies, Naarden, The Netherlands, 29−31 January 2016. Neuromuscul Disord 2016; 26: 624–633.